Doodipala S. Reddy

Reddy, D. S. (2008). [Review of Mass spectrometric assay and physiological-pharmacological activity of androgenic neurosteroids]. Neurochemistry International, 52(4-5), 541–553.

Reddy, D. S., & Zeng, Y. C. (2007). Differential anesthetic activity of ketamine and the GABAergic neurosteroid allopregnanolone in mice lacking progesterone receptor a and B subtypes. Methods and Findings in Experimental and Clinical Pharmacology, 29(10), 659–664. https://doi.org/10.1358/mf.2007.29,10.1147766

Rao, M. S., Hattiangady, B., Reddy, D. S., & Shetty, A. K. (2006). Hippocampal neurodegeneration, spontaneous seizures, and mossy fiber sprouting in the F344 rat model of temporal lobe epilepsy. JOURNAL OF NEUROSCIENCE RESEARCH, 83(6), 1088–1105. https://doi.org/10.1002/jnr.20802

Reddy, D. S. (2006). Physiological role of adrenal deoxycorticosterone-derived neuroactive steroids in stress-sensitive conditions. NEUROSCIENCE, 138(3), 911–920. https://doi.org/10.1016/j.neuroscience.2005.10.016

Reddy, D. S., Venkatarangan, L., Chien, B., & Ramu, K. (2005). A high-performance liquid chromatography-tandem mass spectrometry assay of the androgenic neurosteroid 3 alpha-androstanediol (5 alpha-androstane-3 alpha,17 beta-diol) in plasma. STEROIDS, 70(13), 879–885. https://doi.org/10.1016/j.steroids.2005.05.007

Reddy, D. S., & Apanites, L. A. (2005). Anesthetic effects of progesterone are undiminished in progesterone receptor knockout mice. BRAIN RESEARCH, 1033(1), 96–101. https://doi.org/10.1016/j.brainres.2004.11.026

Reddy, D. S., BW O'Malley, & Rogawski, M. A. (2005). Anxiolytic activity of progesterone in progesterone receptor knockout mice. NEUROPHARMACOLOGY, 48(1), 14–24. https://doi.org/10.1016/j.neuropharm.2004.09.002

Reddy, D. S., Castaneda, D. C., BW O'Malley, & Rogawski, M. A. (2004). Anticonvulsant activity of progesterone and neurosteroids in progesterone receptor knockout mice. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 310(1), 230–239. https://doi.org/10.1124/jpet.104.065268

Reddy, D. S. (2004). Anticonvulsant activity of the testosterone-derived neurosteroid 3 alpha-androstanediol. NeuroReport, 15(3), 515–518. https://doi.org/10.1097/01.wnr.0000113064.17279.32

Reddy, D. S., & Woodward, R. (2004). [Review of Ganaxolone: a prospective overview]. DRUGS OF THE FUTURE, 29(3), 227–242. https://doi.org/10.1358/dof.2004.029.03.793135

Reddy, D. S. (2004). [Review of Pharmacology of catamenial epilepsy]. Methods and Findings in Experimental and Clinical Pharmacology, 26(7), 547–561.

Reddy, D. S. (2004). [Review of Role of neurosteroids in catamenial epilepsy]. EPILEPSY RESEARCH, 62(2-3), 99–118. https://doi.org/10.1016/j.eplepsyres.2004.09.003

Reddy, D. S. (2004). Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3 alpha-androstanediol and 17 beta-estradiol. NEUROSCIENCE, 129(1), 195–207. https://doi.org/10.1016/j.neuroscience.2004.08.002

Reddy, D. S. (2003). Is there a physiological role for the neurosteroid THDOC in stress-sensitive conditions? TRENDS IN PHARMACOLOGICAL SCIENCES, 24(3), 103–106. https://doi.org/10.1016/S0165-6147(03)00023-3

Reddy, D. S. (2002). [Review of Newer gabaergic agents for pharmacotherapy of infantile spasms]. DRUGS OF TODAY, 38(10), 657–675. https://doi.org/10.1358/dot.2002.38.10.820139

Reddy, D. S. (2002). [Review of The clinical potentials of endogenous neurosteroids]. DRUGS OF TODAY, 38(7), 465–485. https://doi.org/10.1358/dot.2002.38.7.820115